Skip to main content
Fig. 2 | BMC Pediatrics

Fig. 2

From: Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study

Fig. 2

Effectiveness of a complete primary series of BNT162b2 compared with being unvaccinated. Note: Children were eligible for inclusion on or after the date BNT162b2 was authorized for their age group (December 11, 2020, for ages 16–17 years; May 10, 2021, for ages 12–15 years; October 29, 2021, for ages 5–11 years). CI = confidence interval; COVID-19 = coronavirus disease 2019; VE = vaccine effectiveness

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us